Summit plans to take ivonescimab to FDA, even with subpar OS data

Summit Therapeutics says it will submit an application to the FDA by the end of the year to review its PD-1xVEGF bispecific antibody, pressing forward with the program despite a mixed Phase 3 readout last ...